Details
Stereochemistry | ACHIRAL |
Molecular Formula | C13H10ClN3O4S2 |
Molecular Weight | 371.819 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C(C(=O)NC2=CC=CC=N2)=C(O)C3=C(C=C(Cl)S3)S1(=O)=O
InChI
InChIKey=WLHQHAUOOXYABV-UHFFFAOYSA-N
InChI=1S/C13H10ClN3O4S2/c1-17-10(13(19)16-9-4-2-3-5-15-9)11(18)12-7(23(17,20)21)6-8(14)22-12/h2-6,18H,1H3,(H,15,16,19)
DescriptionSources: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Xefo_30/WC500009083.pdfCurator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB06725
Sources: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Xefo_30/WC500009083.pdf
Curator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB06725
Lornoxicam (Xefo®) is a nonsteroidal anti-inflammatory drug of the oxicam class with analgesic, anti-inflammatory and antipyretic properties. It differs from other oxicam compounds in its potent inhibition of prostaglandin biosynthesis, a property that explains the particularly pronounced efficacy of the drug. The inhibition of the cyclooxygenase enzymes (COX-1 and COX-2) by lornoxicam (Xefo®) leads to desensitisation of peripheral nociceptors and consequently inhibition of inflammation. A central effect on nociception which seems to be independent of anti-inflammatory effects has also been suggested.
CNS Activity
Originator
Sources: https://www.google.com/patents/US4180662
Curator's Comment: # Hoffmann-La Roche Inc.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL221 |
0.003 µM [IC50] | ||
Target ID: CHEMBL230 |
0.008 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | XEFO Approved UseShort-term relief of acute mild to moderate pain.
Symptomatic relief of pain and inflammation in osteoarthritis.
Symptomatic relief of pain and inflammation in rheumatoid arthritis. |
|||
Palliative | XEFO Approved UseShort-term relief of acute mild to moderate pain.
Symptomatic relief of pain and inflammation in osteoarthritis.
Symptomatic relief of pain and inflammation in rheumatoid arthritis. |
|||
Palliative | XEFO Approved UseShort-term relief of acute mild to moderate pain.
Symptomatic relief of pain and inflammation in osteoarthritis.
Symptomatic relief of pain and inflammation in rheumatoid arthritis. |
PubMed
Title | Date | PubMed |
---|---|---|
Lornoxicam. A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions. | 1996 Apr |
|
Introduction: mechanism of action of NSAIDs. | 1996 Apr |
|
Lornoxicam, a new potent NSAID with an improved tolerability profile. | 2000 Jan |
Patents
Sample Use Guides
Pain:
8-16 mg lornoxicam (Xefo®) daily divided into 2 or 3 doses. Maximum recommended daily dose is 16 mg.
Osteoarthritis and Rheumatoid arthritis:
Initial recommended dose is 12 mg lornoxicam (Xefo®) daily divided into 2 or 3 doses. Maintenance dose should not exceed 16 mg lornoxicam daily.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10450786
In HEL/Mono Mac 6 human cells, lornoxicam showed a balanced inhibition of COX-1/-2 exhibiting the lowest IC50 (0.003 microM/0.008 microM) of the large panel of non steroidal antiinflammatory drugs tested. Similar results were obtained in the whole blood for COX-1/-2 (IC50 values of 0.13 microM for both isoenzymes). NO formation was dose-dependently inhibited by lornoxicam (IC50 of 65 microM) whereas piroxicam, diclofenac, ibuprofen, ketorolac and naproxen inhibited the NO formation markedly less. In stimulated human monocytic cells (THP-1), lornoxicam showed a marked inhibition of IL-6 formation (IC50 54 microM) while the formation ofTNF-alpha, IL-1beta and IL-8 was only moderately affected.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QM01AC05
Created by
admin on Fri Dec 15 15:06:06 GMT 2023 , Edited by admin on Fri Dec 15 15:06:06 GMT 2023
|
||
|
NCI_THESAURUS |
C257
Created by
admin on Fri Dec 15 15:06:06 GMT 2023 , Edited by admin on Fri Dec 15 15:06:06 GMT 2023
|
||
|
WHO-ATC |
M01AC05
Created by
admin on Fri Dec 15 15:06:06 GMT 2023 , Edited by admin on Fri Dec 15 15:06:06 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C059451
Created by
admin on Fri Dec 15 15:06:06 GMT 2023 , Edited by admin on Fri Dec 15 15:06:06 GMT 2023
|
PRIMARY | |||
|
ER09126G7A
Created by
admin on Fri Dec 15 15:06:06 GMT 2023 , Edited by admin on Fri Dec 15 15:06:06 GMT 2023
|
PRIMARY | |||
|
m6910
Created by
admin on Fri Dec 15 15:06:06 GMT 2023 , Edited by admin on Fri Dec 15 15:06:06 GMT 2023
|
PRIMARY | Merck Index | ||
|
BB-58
Created by
admin on Fri Dec 15 15:06:06 GMT 2023 , Edited by admin on Fri Dec 15 15:06:06 GMT 2023
|
PRIMARY | |||
|
6233
Created by
admin on Fri Dec 15 15:06:06 GMT 2023 , Edited by admin on Fri Dec 15 15:06:06 GMT 2023
|
PRIMARY | |||
|
CHEMBL1569487
Created by
admin on Fri Dec 15 15:06:06 GMT 2023 , Edited by admin on Fri Dec 15 15:06:06 GMT 2023
|
PRIMARY | |||
|
1609
Created by
admin on Fri Dec 15 15:06:06 GMT 2023 , Edited by admin on Fri Dec 15 15:06:06 GMT 2023
|
PRIMARY | |||
|
31783
Created by
admin on Fri Dec 15 15:06:06 GMT 2023 , Edited by admin on Fri Dec 15 15:06:06 GMT 2023
|
PRIMARY | |||
|
20890
Created by
admin on Fri Dec 15 15:06:06 GMT 2023 , Edited by admin on Fri Dec 15 15:06:06 GMT 2023
|
PRIMARY | RxNorm | ||
|
Lornoxicam
Created by
admin on Fri Dec 15 15:06:06 GMT 2023 , Edited by admin on Fri Dec 15 15:06:06 GMT 2023
|
PRIMARY | |||
|
759620
Created by
admin on Fri Dec 15 15:06:06 GMT 2023 , Edited by admin on Fri Dec 15 15:06:06 GMT 2023
|
PRIMARY | |||
|
54690031
Created by
admin on Fri Dec 15 15:06:06 GMT 2023 , Edited by admin on Fri Dec 15 15:06:06 GMT 2023
|
PRIMARY | |||
|
70374-39-9
Created by
admin on Fri Dec 15 15:06:06 GMT 2023 , Edited by admin on Fri Dec 15 15:06:06 GMT 2023
|
PRIMARY | |||
|
100000090751
Created by
admin on Fri Dec 15 15:06:06 GMT 2023 , Edited by admin on Fri Dec 15 15:06:06 GMT 2023
|
PRIMARY | |||
|
DTXSID6046133
Created by
admin on Fri Dec 15 15:06:06 GMT 2023 , Edited by admin on Fri Dec 15 15:06:06 GMT 2023
|
PRIMARY | |||
|
DB06725
Created by
admin on Fri Dec 15 15:06:06 GMT 2023 , Edited by admin on Fri Dec 15 15:06:06 GMT 2023
|
PRIMARY | |||
|
C72140
Created by
admin on Fri Dec 15 15:06:06 GMT 2023 , Edited by admin on Fri Dec 15 15:06:06 GMT 2023
|
PRIMARY | |||
|
SUB08589MIG
Created by
admin on Fri Dec 15 15:06:06 GMT 2023 , Edited by admin on Fri Dec 15 15:06:06 GMT 2023
|
PRIMARY |
ACTIVE MOIETY